| 名稱 | PD-L1/CD80 CD86 aAPC Cell |
| 型號 | CBP74151 |
| 報價 | ![]() |
| 特點 | PD-L1/CD80&CD86 aAPC Cell |
產品搜索
相關文章
聯系我們
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區緯地路9號
Email: zhangxiangwen@cobioer.com
產品展示 / PRODUCTS
- 詳細內容
| I. Background | |
免疫檢查點抑制劑(抗 CTLA4、抗 PD1、抗 PDL1、抗 PD1/PDL1 與抗 CTLA4 聯合治 療)治療癌癥患者是近年來腫瘤學領域的重大突破,是一種新型的癌癥治療手段。 | |
| II. Description | |
PDL1 CD80&CD86 aAPC Cell 作為 PD1&CTLA4 Dual Effector Reporter Cell 的靶細胞,很好的模擬了體內 PD1&CTLA4 的信號轉導過程,原理見下圖所示。
Figure 1. PDL1 CD80&CD86 aAPC Cell 細胞模型原理圖 | |
| III. Introduction | |
| Expressed gene: | PD-1、CD80、CD86 |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1 μg/ml Puromycin+800 μg/ml Hygromycin B |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| IV. Representative Data | |
Figure 1. Dose Response of Blocking Antibodies in PD1&CTLA4 Dual Effector Reporter Cell (C16) With PD-L1 CD80&CD86 aAPC Cell (C14). | |
| |






